Mark Connor

Professor

  • 4934 Citations
  • 40 h-Index
1991 …2019
If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

I am Pharmacologist interested in analgesics and other psychoactive drugs, particularly cannabinoids and opioids. My lab studies how opioids, cannabinoids and related molecules interact with G protein coupled receptors and ion channels to exert their effects. Currently my work is focussed on how clinically used opioids interact with naturally occuring variants of human opioid receptors, the pharmacology and toxicity of emerging synthetic cannabinoid receptors agonists (Spice/K2) and the molecular mechanisms underlying the potential therapeutic actions of cannabis and its components.

Education/Academic qualification

Pharmacology, PhD, University of Washington

Pharmacology, Genetics, BSc (Hons), University of Sydney

Fingerprint Dive into the research topics where Mark Connor is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 2 Similar Profiles
mu Opioid Receptor Medicine & Life Sciences
Opioid Analgesics Medicine & Life Sciences
Cannabinoids Medicine & Life Sciences
Pharmacology Medicine & Life Sciences
Neurons Medicine & Life Sciences
Periaqueductal Gray Medicine & Life Sciences
Cannabinoid Receptor CB2 Medicine & Life Sciences
Cannabinoid Receptor Agonists Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2008 2019

Research Outputs 1991 2019

Absence of entourage: terpenoids commonly found in Cannabis sativa do not modulate the functional activity of Δ9-THC at human CB1 and CB2 receptors

Santiago, M., Sachdev, S., Arnold, J. C., McGregor, I. & Connor, M., 1 Sep 2019, In : Cannabis and Cannabinoid Research. 4, 3, p. 165-176 12 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Cannabinoid Receptors
Dronabinol
Terpenes
Cannabis
Potassium Channels

Brodifacoum does not modulate human cannabinoid receptor-mediated hyperpolarization of AtT20 cells or inhibition of adenylyl cyclase in HEK 293 cells

Sachdev, S., Boyd, R., Grimsey, N. L., Santiago, M. & Connor, M., 25 Sep 2019, In : PeerJ. 2019, 9, p. 1-15 15 p., e7733.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
brodifacoum
Cannabinoid Receptors
adenylate cyclase
HEK293 Cells
Adenylyl Cyclases

Cannabichromene is a Cannabinoid CB2 receptor agonist

Udoh, M., Santiago, M., Devenish, S., McGregor, I. & Connor, M., 1 Aug 2019, (Accepted/In press) In : British Journal of Pharmacology. 11 p.

Research output: Contribution to journalArticleResearchpeer-review

Cannabinoid Receptor Agonists
Cannabinoid Receptor CB2
Cannabinoid Receptor CB1
Dronabinol
Cell Surface Receptors

Dark classics in Chemical Neuroscience: Δ 9 -tetrahydrocannabinol

Banister, S. D., Arnold, J. C., Connor, M., Glass, M. & Mcgregor, I. S., 15 May 2019, In : ACS Chemical Neuroscience. 10, 5, p. 2160-2175 16 p.

Research output: Contribution to journalReview articleResearchpeer-review

Dronabinol
Neurosciences
Cannabis
Medical Marijuana
Pharmacology

In vitro determination of the CB1 efficacy of illicit synthetic cannabinoids

Sachdev, S., Vemuri, K., Banister, S. D., Longworth, M., Kassiou, M., Santiago, M., Makriyannis, A. & Connor, M., 14 Aug 2019, (Accepted/In press) In : British Journal of Pharmacology.

Research output: Contribution to journalArticleResearchpeer-review

Artificial Receptors
Cannabinoid Receptor Agonists
Cannabinoids
Dronabinol
Cannabinoid Receptor CB1